Please use this identifier to cite or link to this item:
Full metadata record
|dc.contributor.author||Mackenzie, Peter I||-|
|dc.contributor.author||Somogyi, Andrew A||-|
|dc.contributor.author||Miners, John O||-|
|dc.identifier.citation||Pharmacological research 2017-02; 116: 7-19||-|
|dc.description.abstract||Metabolism facilitates the elimination, detoxification and excretion in urine or bile (as biotransformation products) of a myriad of structurally diverse drugs and other chemicals. The metabolism of drugs, non-drug xenobiotics and many endogenous compounds is catalyzed by families of drug metabolizing enzymes (DMEs). These include the hemoprotein-containing cytochromes P450, which function predominantly as monooxygenases, and conjugation enzymes that transfer a sugar, sulfate, acetate or glutathione moiety to substrates containing a suitable acceptor functional group. Drug and chemical metabolism, especially the enzymes that catalyse these reactions, has been the research focus of several groups in Australia for over four decades. In this review, we highlight the role of recent and current drug metabolism research in Australia, including elucidation of the structure and function of enzymes from the various DME families, factors that modulate enzyme activity in humans (e.g. drug-drug interactions, gene expression and genetic polymorphism) and the application of in vitro approaches for the prediction of drug metabolism parameters in humans, along with the broader pharmacological/clinical pharmacological and toxicological significance of drug metabolism and DMEs and their relevance to drug discovery and development, and to clinical practice.||-|
|dc.subject.mesh||Cytochrome P-450 Enzyme System||-|
|dc.title||Advances in drug metabolism and pharmacogenetics research in Australia.||-|
|Appears in Collections:||Scholarly and Clinical|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.